Celltrion sells US copies of 4 of the blockbuster drugs on this tracker and has 5 filed or in development. Those brands earned $79.5B in 2025. Of the 70 makers we follow, 7 are lined up to copy more of these drugs.
| Drug | Celltrion's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Stelara SteqeymaBiosimilar · Johnson & Johnson · US LOE 2025 | FDA-approved 17 Dec 2024; launched Mar 2025; interchangeable | 7 on sale · 0 approvedof 7 other makers listed | $6.1B |
| Prolia StobocloBiosimilar · Amgen · US LOE 2025 | FDA-approved 28 Feb 2025; launched Jul 2025; interchangeable | 6 on sale · 3 approvedof 10 other makers listed | $4.4B |
| Xgeva OsenveltBiosimilar · Amgen · US LOE 2025 | FDA-approved 28 Feb 2025; launched Jul 2025; interchangeable | 5 on sale · 4 approvedof 10 other makers listed | $2.1B |
| Xolair OmlycloBiosimilar · Roche / Novartis · US LOE 2026 | FDA-approved 7 Mar 2025; launched 5 Oct 2026; interchangeable; first interchangeable biosimilar; its exclusivity as the only interchangeable ended 7 Sep 2026 | 0 on sale · 0 approvedof 1 other maker listed | ≈$5.4B |
| Drug | Celltrion's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Keytruda CT-P51Biosimilar · Merck · US LOE 2028 | In clinical trials. Phase 3; filed in Korea | 0 on sale · 0 approvedof 9 other makers listed | $31.7B |
| Darzalex CT-P44Biosimilar · Johnson & Johnson · US LOE 2029 | In clinical trials | 0 on sale · 0 approvedof 1 other maker listed | $14.3B |
| Cosentyx CT-P55Biosimilar · Novartis · US LOE 2029 | In clinical trials. Filed in Canada (Jun 2026) and the EU (Jul 2026) | 0 on sale · 0 approvedof 1 other maker listed | $6.7B |
| Taltz CT-P52Biosimilar · Eli Lilly · US LOE 2030 | Early development | 0 on sale · 0 approvedof 2 other makers listed | $3.6B |
| Tremfya CT-P68Biosimilar · Johnson & Johnson · US LOE 2031 | In clinical trials. Phase 1 approved in Korea (Jul 2026) | 0 on sale · 0 approvedof 3 other makers listed | $5.2B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not Celltrion's own sales. See the launch tracker →
Each row is a copy Celltrion sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Celltrion's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Celltrion's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: Stock Analysis.